Skip to main content
main-content

The independent medical news service

Breast cancer

22-09-2020 | Oncology | News | Article

monarchE: Adjuvant abemaciclib reduces relapse risk in high-risk early breast cancer

Adding abemaciclib to adjuvant endocrine therapy significantly reduces the risk for recurrence in patients with high-risk, hormone receptor-positive, HER2-negative, early breast cancer, show phase 3 trial findings.

20-09-2020 | Oncology | News | Article

IMpassion130: ‘Clinically meaningful’ OS boost with atezolizumab in PD-L1-positive advanced TNBC

The final overall survival results of the IMpassion130 trial continue to support the first-line use of atezolizumab plus nab-paclitaxel in PD-L1-expressing patients with metastatic triple-negative breast cancer.

18-09-2020 | Oncology | News | Article

FDA issues alert on atezolizumab–paclitaxel duo in breast cancer

Click through for the details of this announcement

16-09-2020 | Oncology | Highlight | Article

ctDNA accurately identifies breast cancer targeted therapy candidates

Testing for circulating tumor DNA accurately identifies patients with breast cancer suitable for mutation-targeted therapies, results of the phase 2a plasmaMATCH trial show.

14-09-2020 | Oncology | News | Article

Long-term recurrence rates similar with partial vs whole breast irradiation

Long-term ipsilateral breast tumor recurrence rates are similar whether women are treated with accelerated partial-breast irradiation or whole-breast irradiation, results of the phase 3 APBI-IMRT-Florence trial show.

09-09-2020 | Oncology | News | Article

Meta-analysis indicates benefit of shorter trastuzumab duration in early breast cancer

In patients with early-stage breast cancer, shorter durations of adjuvant trastuzumab therapy are noninferior to the standard 1-year schedule with regard to disease-free survival, suggests an individual patient data meta-analysis.

02-09-2020 | Oncology | News | Article

Veliparib plus chemotherapy improves BRCA-mutated breast cancer PFS

Combining the PARP inhibitor veliparib with carboplatin and paclitaxel delays disease progression and death in patients with BRCA-mutated, HER2-negative advanced breast cancer, show data from the BROCADE3 trial.

27-08-2020 | Oncology | News | Article

Adjuvant paclitaxel–carboplatin a potential alternative for TNBC patients

Phase 3 results from China suggest that paclitaxel plus carboplatin could be an adjuvant therapy option for patients with operable triple-negative breast cancer.

25-08-2020 | Oncology | News | Article

Cancer diagnoses in USA fall during COVID-19 pandemic

US researchers report “a significant decline” in the numbers of new diagnoses of six tumor types following the SARS-CoV-2 outbreak.

21-08-2020 | Oncology | News | Article

Mammogram screening from age 40 may reduce breast cancer mortality risk

Extending mammography screening to include women in their 40s may reduce breast cancer mortality rates compared with a later screening induction without increasing the risk for overdiagnosis, the UK Age trial investigators report.

20-08-2020 | Oncology | News | Article

Long-term TARGIT-A data support single-dose intraoperative breast cancer radiotherapy

The 5-year results of the TARGIT-A trial have demonstrated the noninferiority of risk-adapted, single-dose targeted intraoperative radiotherapy delivered during lumpectomy to conventional radiotherapy for the adjuvant treatment of early-stage breast cancer.

13-08-2020 | Oncology | News | Article

Fall in breast cancer screening, diagnosis, and treatment due to COVID-19

Rates of breast cancer surgery, imaging, and genetic testing in the USA have dropped during the COVID-19 pandemic, study findings suggest.

06-08-2020 | Oncology | News | Article

Late relapse in ER-positive, early breast cancer influenced by genetic variants

A post-hoc analysis of the BIG 1–98 trial has identified genetic variants associated with the risk for recurrence after 5 years of adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive, HER2-negative, early-stage breast cancer.

05-08-2020 | Oncology | News | Article

Neratinib boosts PFS in pretreated advanced HER2-positive breast cancer

Supplementing capecitabine with neratinib instead of lapatinib is associated with a significant improvement in the progression-free survival of previously treated patients with metastatic HER2-positive breast cancer, shows the phase 3 NALA trial.

31-07-2020 | Oncology | News | Article

Cancer diagnostic delays due to COVID-19 may lead to high excess mortality

Two modelling studies published in The Lancet Oncology show the impact cancer diagnostic delays due to COVID-19 could have in England, with some scenarios suggesting over a 1000 people could die unnecessarily.

30-07-2020 | Oncology | News | Article

Older age does not rule out chemotherapy benefit among breast cancer patients

A database analysis indicates that adjuvant chemotherapy may prolong overall survival in patients aged at least 70 years with node- and estrogen receptor-positive breast cancer and multiple comorbidities.

27-07-2020 | Oncology | News | Article

Guidance proposed for managing breast cancer during COVID-19

A stage- and subtype-specific approach for the management of breast cancer during the COVID-19 outbreak has been published in JCO Oncology Practice.

22-07-2020 | Oncology | News | Article

Liquid biopsy may predict early-stage TNBC recurrence

The presence of circulating tumor DNA and circulating tumor cells in postsurgical samples is associated with relapse and poor outcomes in early-stage triple-negative breast cancer patients with an incomplete pathologic response to neoadjuvant chemotherapy, research suggests.

21-07-2020 | Oncology | News | Article

BMI modifies adjuvant docetaxel efficacy in early breast cancer

Women with early-stage breast cancer have a differential response to adjuvant docetaxel therapy according to their BMI, finds a post-hoc analysis of a phase 3 trial.

17-07-2020 | Oncology | News | Article

Surgical delays due to COVID-19 significantly impact cancer survival

UK researchers have called for urgent action to be taken to avoid unnecessary cancer deaths as a result of delayed surgery due to the COVID-19 pandemic.

Image Credits